The Goodwin Life Sciences and Public M&A teams advised AlloVir (Nasdaq: ALVR) on its definitive merger agreement to combine with Kalaris Therapeutics, a clinical-stage biopharmaceutical company founded by Samsara BioCapital, in an all-stock transaction. The combined company will focus on the development of TH103, a novel, differentiated anti-VEGF investigational therapy for patients with neovascular and exudative retinal diseases. The combined company is expected to trade on Nasdaq under the ticker symbol “KLRS.”
Upon completion of the merger, the combined company is expected to have approximately $100 million in cash. The merger is subject to stockholder approval of both companies, the effectiveness of a registration statement to be filed with the U.S. Securities and Exchange Commission to register the securities to be issued in connection with the merger, AlloVir having a minimum of $95 million of net cash as of the closing, and the satisfaction of customary closing conditions.
AlloVir is an allogeneic T cell immunotherapy company that was focused on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems.
The Goodwin team was led by Tevia Pollard and Danielle Lauzon, and included William Stanton, Christopher James Gravallese, Andrea Akinbola and Keelin Anne Fitzsimmons (Public M&A), Christpher Huntsman, Ryan Donahoe, Alexandra Singer and Matthew Kane (Corporate), Sarah Bock and Andre Amorim (Employee Benefits), Christina Lewis, Alastair Papworth and Lauren NuDelman (Labor and Employment), Dan Karelitz (Tax), Caroline Bullerjahn (Litigation), Justin Pierce, Gozde Guckaya and Katerina Dee (Global Trade), Heath Ingram (Healthcare), Steven Tjoe (FDA Regulatory), Noelle Dubiansky (Licensing), Jackie Klosek and Jacob Lee (Privacy), Reid Bagwell and Emeka Nduka-Eze (Debt), and Arman Oruc, John Goheen and Simone Waterbury (Antitrust).
For more information, please read the press release.